Annual EBITDA
-$19.91 M
-$1.79 M-9.88%
31 December 2023
Summary:
Inhibikase Therapeutics annual earnings before interest, taxes, depreciation & amortization is currently -$19.91 million, with the most recent change of -$1.79 million (-9.88%) on 31 December 2023. During the last 3 years, it has fallen by -$17.09 million (-606.49%). IKT annual EBITDA is now -838.33% below its all-time high of -$2.12 million, reached on 31 December 2018.IKT EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$5.82 M
-$776.90 K-15.40%
30 September 2024
Summary:
Inhibikase Therapeutics quarterly earnings before interest, taxes, depreciation & amortization is currently -$5.82 million, with the most recent change of -$776.90 thousand (-15.40%) on 30 September 2024. Over the past year, it has dropped by -$1.06 million (-22.23%). IKT quarterly EBITDA is now -1306.35% below its all-time high of -$413.90 thousand, reached on 30 June 2020.IKT Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$20.04 M
-$1.06 M-5.58%
30 September 2024
Summary:
Inhibikase Therapeutics TTM earnings before interest, taxes, depreciation & amortization is currently -$20.04 million, with the most recent change of -$1.06 million (-5.58%) on 30 September 2024. Over the past year, it has dropped by -$192.40 thousand (-0.97%). IKT TTM EBITDA is now -1056.44% below its all-time high of -$1.73 million, reached on 31 March 2019.IKT TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
IKT EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -9.9% | -22.2% | -1.0% |
| 3 y3 years | -606.5% | -30.2% | -83.4% |
| 5 y5 years | -838.3% | -383.2% | -279.8% |
IKT EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -606.5% | at low | -34.4% | +3.7% | -83.4% | at low |
| 5 y | 5 years | -838.3% | at low | -1306.3% | +3.7% | -882.3% | at low |
| alltime | all time | -838.3% | at low | -1306.3% | +3.7% | -1056.4% | at low |
Inhibikase Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$5.82 M(+15.4%) | -$20.04 M(+5.6%) |
| June 2024 | - | -$5.04 M(+5.6%) | -$18.98 M(-5.0%) |
| Mar 2024 | - | -$4.78 M(+8.6%) | -$19.98 M(+0.3%) |
| Dec 2023 | -$19.91 M(+9.9%) | -$4.40 M(-7.7%) | -$19.91 M(+0.3%) |
| Sept 2023 | - | -$4.76 M(-21.2%) | -$19.85 M(+1.3%) |
| June 2023 | - | -$6.04 M(+28.3%) | -$19.59 M(+7.7%) |
| Mar 2023 | - | -$4.71 M(+8.8%) | -$18.19 M(+0.4%) |
| Dec 2022 | -$18.12 M(+22.7%) | -$4.33 M(-4.0%) | -$18.12 M(-3.8%) |
| Sept 2022 | - | -$4.51 M(-2.8%) | -$18.83 M(+0.2%) |
| June 2022 | - | -$4.64 M(-0.0%) | -$18.79 M(+12.0%) |
| Mar 2022 | - | -$4.64 M(-8.0%) | -$16.78 M(+13.6%) |
| Dec 2021 | -$14.77 M | -$5.04 M(+12.8%) | -$14.77 M(+35.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2021 | - | -$4.47 M(+70.1%) | -$10.93 M(+53.5%) |
| June 2021 | - | -$2.63 M(+0.1%) | -$7.12 M(+45.2%) |
| Mar 2021 | - | -$2.63 M(+118.6%) | -$4.90 M(+74.0%) |
| Dec 2020 | -$2.82 M(-50.5%) | -$1.20 M(+80.9%) | -$2.82 M(+38.2%) |
| Sept 2020 | - | -$663.70 K(+60.4%) | -$2.04 M(-21.0%) |
| June 2020 | - | -$413.90 K(-23.4%) | -$2.58 M(-42.7%) |
| Mar 2020 | - | -$540.00 K(+27.9%) | -$4.51 M(-20.9%) |
| Dec 2019 | -$5.70 M(+168.5%) | -$422.30 K(-64.9%) | -$5.70 M(+8.0%) |
| Sept 2019 | - | -$1.20 M(-48.5%) | -$5.28 M(+29.6%) |
| June 2019 | - | -$2.34 M(+35.0%) | -$4.07 M(+135.0%) |
| Mar 2019 | - | -$1.73 M | -$1.73 M |
| Dec 2018 | -$2.12 M | - | - |
FAQ
- What is Inhibikase Therapeutics annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Inhibikase Therapeutics?
- What is Inhibikase Therapeutics annual EBITDA year-on-year change?
- What is Inhibikase Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Inhibikase Therapeutics?
- What is Inhibikase Therapeutics quarterly EBITDA year-on-year change?
- What is Inhibikase Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Inhibikase Therapeutics?
- What is Inhibikase Therapeutics TTM EBITDA year-on-year change?
What is Inhibikase Therapeutics annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of IKT is -$19.91 M
What is the all time high annual EBITDA for Inhibikase Therapeutics?
Inhibikase Therapeutics all-time high annual earnings before interest, taxes, depreciation & amortization is -$2.12 M
What is Inhibikase Therapeutics annual EBITDA year-on-year change?
Over the past year, IKT annual earnings before interest, taxes, depreciation & amortization has changed by -$1.79 M (-9.88%)
What is Inhibikase Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of IKT is -$5.82 M
What is the all time high quarterly EBITDA for Inhibikase Therapeutics?
Inhibikase Therapeutics all-time high quarterly earnings before interest, taxes, depreciation & amortization is -$413.90 K
What is Inhibikase Therapeutics quarterly EBITDA year-on-year change?
Over the past year, IKT quarterly earnings before interest, taxes, depreciation & amortization has changed by -$1.06 M (-22.23%)
What is Inhibikase Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of IKT is -$20.04 M
What is the all time high TTM EBITDA for Inhibikase Therapeutics?
Inhibikase Therapeutics all-time high TTM earnings before interest, taxes, depreciation & amortization is -$1.73 M
What is Inhibikase Therapeutics TTM EBITDA year-on-year change?
Over the past year, IKT TTM earnings before interest, taxes, depreciation & amortization has changed by -$192.40 K (-0.97%)